Westfield Capital Management
PCRX icon

Westfield Capital Management’s Pacira BioSciences PCRX Stock Holding History

Westfield Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-29,960
Closed -$1.16M – 251
2022
Q4 		$1.16M Sell
29,960
-490,737
-94% -$23.9M 0.01% 204
2022
Q3 		$27.7M Sell
520,697
-4,839
-0.9% -$269K 0.22% 154
2022
Q2 		$30.6M Buy
525,536
+107,034
+26% +$7.01M 0.24% 140
2022
Q1 		$31.9M Sell
418,502
-674,980
-62% -$45M 0.2% 144
2021
Q4 		$65.8M Sell
1,093,482
-32,837
-3% -$1.81M 0.39% 90
2021
Q3 		$63.1M Buy
1,126,319
+95,674
+9% +$5.51M 0.38% 93
2021
Q2 		$62.5M Buy
1,030,645
+503,548
+96% +$31.9M 0.37% 100
2021
Q1 		$36.9M Sell
527,097
-399,891
-43% -$28.6M 0.23% 133
2020
Q4 		$55.5M Buy
926,988
+14,213
+2% +$832K 0.33% 107
2020
Q3 		$54.9M Sell
912,775
-448,467
-33% -$26.1M 0.36% 96
2020
Q2 		$71.4M Buy
1,361,242
+361,072
+36% +$15.1M 0.49% 67
2020
Q1 		$33.5M Buy
1,000,170
+258,781
+35% +$10.8M 0.3% 105
2019
Q4 		$33.6M Buy
741,389
+226,460
+44% +$9.62M 0.24% 131
2019
Q3 		$19.6M Buy
+514,929
New +$20.6M 0.16% 159
2018
Q2 		– Sell
-834,282
Closed -$26M – 267
2018
Q1 		$26M Sell
834,282
-411,641
-33% -$14.7M 0.2% 158
2017
Q4 		$56.9M Sell
1,245,923
-39,927
-3% -$1.58M 0.43% 89
2017
Q3 		$48.3M Buy
1,285,850
+64,510
+5% +$2.6M 0.37% 100
2017
Q2 		$58.3M Sell
1,221,340
-387,507
-24% -$18M 0.5% 73
2017
Q1 		$73.4M Buy
1,608,847
+5,166
+0.3% +$223K 0.63% 44
2016
Q4 		$51.8M Buy
1,603,681
+365,273
+29% +$12.2M 0.45% 84
2016
Q3 		$42.4M Sell
1,238,408
-95,460
-7% -$3.74M 0.34% 99
2016
Q2 		$45M Buy
1,333,868
+640,814
+92% +$31.5M 0.37% 92
2016
Q1 		$36.7M Buy
693,054
+23,494
+4% +$1.37M 0.28% 114
2015
Q4 		$51.4M Sell
669,560
-719,604
-52% -$40.7M 0.35% 98
2015
Q3 		$57.1M Sell
1,389,164
-104,888
-7% -$6.42M 0.4% 85
2015
Q2 		$106M Buy
1,494,052
+766,062
+105% +$60.3M 0.64% 49
2015
Q1 		$64.7M Buy
+727,990
New +$73.9M 0.37% 93

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Westfield Capital Management's PCRX Position: Q1 2023 in Review

Westfield Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 29,960 shares — an estimated $1.16M sold.

Westfield Capital Management first reported a position in PCRX in Q1 2015 and held it in 27 quarters. The position peaked at $106M in Q2 2015. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

  • Westfield Capital Management reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
  • Westfield Capital Management sold 29,960 Pacira BioSciences shares in Q1 2023, an estimated $1.16M.
  • Westfield Capital Management first reported a position in Pacira BioSciences in Q1 2015 and held it in 27 quarters.
  • Westfield Capital Management's Pacira BioSciences position peaked at $106M in Q2 2015.
  • 267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Westfield Capital Management's 13F filing for Q1 2023, filed 12 May 2023.